Concepedia

Isabella Attinger-Toller

IA

4

Publications

171

Citations

4

H-Index

2014

Active since

Affiliations

Janssen (Switzerland)(Current)

Johnson & Johnson (Switzerland)

Isabella Attinger-Toller is an author at Janssen (Switzerland) specializing in immunology, immunotherapy, and medicine.

Top concepts

Publications per year

2014–2018

4

Publications

4

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Michela Silacci, Wibke Lembke, Richard Woods et al. · mAbs · 2015 · 90 citations · Full text

, , +19

A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

Simon Brack, Isabella Attinger-Toller, Babette Schade et al. · Molecular Cancer Therapeutics · 2014 · 42 citations · Full text

Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

Ulrich Wuellner, Kristina Klupsch, Fabian Buller et al. · Antibodies · 2015 · 25 citations · Full text

, , +13

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Kristina Klupsch, Vanessa Baeriswyl, Roland W. Scholz et al. · Leukemia · 2018 · 14 citations

, , +9

Rows per page

1–4 of 4